Location of Repository

DOMINO-AD protocol : donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT

By R. G. Jones, Bart Sheehan, P. Phillips, Ed Juszczak, J. Adams, Ashley Baldwin, Clive Ballard, Sube Banerjee, Bob Barber, Peter Bentham, R. G. Brown, Alistair S. Burns, Tom Dening, David Findlay, Richard Gray, M. Griffin, Clive Holmes, A. Hughes, Robin Jacoby, T. Johnson, Roy W. Jones, Martin Knapp, James Lindesay, I. G. McKeith, Rupert McShane, Ajay Macharouthu, J. T. O'Brien, Caroline Onions, Peter Passmore, J. P. Raftery, C. W. Ritchie and Robert Howard


Background: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase\ud inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild\ud to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in\ud the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not\ud recommended by the England and Wales National Institute for Health and Clinical Excellence.\ud However, there is little evidence to guide clinicians as to what to prescribe as AD advances; in\ud particular, what to do as the condition progresses from moderate to severe. Options include\ud continuing cholinesterase inhibitors irrespective of decline, adding memantine to cholinesterase\ud inhibitors, or prescribing memantine instead of cholinesterase inhibitors. The aim of this trial is to\ud establish the most effective drug option for people with AD who are progressing from moderate\ud to severe dementia despite treatment with donepezil.\ud Method: DOMINO-AD is a pragmatic, 15 centre, double-blind, randomized, placebo controlled\ud trial. Patients with AD, currently living at home, receiving donepezil 10 mg daily, and with\ud Standardized Mini-Mental State Examination (SMMSE) scores between 5 and 13 are being recruited.\ud Each is randomized to one of four treatment options: continuation of donepezil with memantine\ud placebo added; switch to memantine with donepezil placebo added; donepezil and memantine\ud together; or donepezil placebo with memantine placebo. 800 participants are being recruited and\ud treatment continues for one year. Primary outcome measures are cognition (SMMSE) and activities\ud of daily living (Bristol Activities of Daily Living Scale). Secondary outcomes are non-cognitive\ud dementia symptoms (Neuropsychiatric Inventory), health related quality of life (EQ-5D and\ud DEMQOL-proxy), carer burden (General Health Questionnaire-12), cost effectiveness (using\ud Client Service Receipt Inventory) and institutionalization. These outcomes are assessed at baseline,\ud 6, 18, 30 and 52 weeks. All participants will be subsequently followed for 3 years by telephone\ud interview to record institutionalization.\ud Discussion: There is considerable debate about the clinical and cost effectiveness of anti-dementia\ud drugs. DOMINO-AD seeks to provide clear evidence on the best treatment strategies for those\ud managing patients at a particularly important clinical transition point.\ud Trial registration: Current controlled trials ISRCTN4954503

Topics: RC0321
Publisher: BioMed Central Ltd.
Year: 2009
OAI identifier: oai:wrap.warwick.ac.uk:2151

Suggested articles



  1. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology doi
  2. (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology doi
  3. (1998). A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology doi
  4. (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology doi
  5. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology doi
  6. (2000). A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol doi
  7. (1998). A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease.
  8. (2004). AD2000 Collaborative Group: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD200): randomised double-blind trial. Lancet doi
  9. (1998). and the Doneqezil Study Group: Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med
  10. (2000). and the Galantamine USA-Study Group: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology doi
  11. (1996). Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age and Ageing doi
  12. (1988). Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. doi
  13. (2001). Costing psychiatric interventions.
  14. (2005). den: Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ doi
  15. Donepezil shows significant benefits in global function, cognition, ADL, and behaviour in patients with severe Alzheimer's disease. Neurology 2003, 60(Suppl 1):A413.
  16. (2000). E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ doi
  17. (2001). Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. doi
  18. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ doi
  19. (1984). EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRADA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology doi
  20. (2001). for Clinical Excellence Technology Appraisal Guidance – No 19: Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease.
  21. (2006). for Health and Clinical Excellence Technology Appraisal Guidance – No 111: Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. doi
  22. (2008). for the Memantine MEM-MD-12 Study Group: Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial. Current Alzheimer Research doi
  23. (2002). Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE<12) for up to six months.
  24. (2005). Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess doi
  25. (2005). Memantine for dementia. Cochrane Database Syst Rev doi
  26. (2004). Memantine Treatment in Patients with moderate to severe Alzheimer Disease already receiving Donepezil. JAMA doi
  27. (1975). Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. doi
  28. (1997). Pinol APY: Sample Size Tables for Clinical Studies London:
  29. (1999). Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. doi
  30. (2004). Quarg P: Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. doi
  31. (2003). Scrip: Alzheimer's combination blow for memantine. Scrip
  32. (2008). SM: A multinational, randomized, double-blind, placebo-controlled trial of memantine extendedrelease capsule in patients with moderate to severe Alzheimer's disease. doi
  33. (2004). The Cognitive Benefits of Galantamine are substained for at least 36 months. Arch Neurol doi
  34. (1999). The effects of donepezil in Alzheimer's disease – results from a multinational trial. Dementia Geriatr Cog Disord doi
  35. (2004). The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology doi
  36. (1990). The EuroQol Group: EuroQol – A new facility for the measurement of health related quality of life. Health Policy doi
  37. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology doi
  38. (1997). The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychological Medicine doi
  39. TI: A guide to the standardized Mini-Mental State Examination. Int Psychogeriatr 1997, 9(Suppl 1):87-94. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.